In recent years, circulating tumor DNA (ctDNA) has proven to be a more accurate, reliable, and convenient way to capture ESR1 mutations, making liquid biopsy a great option for regular testing using either Next Generation Sequencing (NGS) or digital droplet PCR (ddPCR). Here, ESR1 is linked to neoplasm.